ArticleThe New England journal of medicine2021
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
Article in The New England journal of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients.Nature communications · 2022Pooled it
- Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis.Infectious diseases of poverty · 2021Pooled it
- Trial
- Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial.The Lancet. Respiratory medicine · 2022Trial
- Efficacy of convalescent plasma for treatment of COVID-19 in Uganda.BMJ open respiratory research · 2021Trial
- NLRP3 inflammasomes at the ARDS-cancer interface: mechanisms and translational hypotheses.Frontiers in immunology · 2026Review
- Rare Disease Drug Repurposing.JAMA network open · 2025Article
- Role of Procalcitonin as a Prognostic Biomarker in Hospitalized COVID-19 Patients: A Comparative Analysis.Biomarker insights · 2025Article
- Drug-target Mendelian randomisation applied to metabolic dysfunction-associated steatotic liver disease: opportunities and challenges.eGastroenterology · 2024Review
- Neutrophil-to-Lymphocyte Ratio and Cytokine Profiling as Predictors of Disease Severity and Survival in Unvaccinated COVID-19 Patients.Vaccines · 2024Article
- Article
- Early pandemic in-hospital outcomes and mortality risk factors in COVID-19 solid organ transplant patients.Proceedings (Baylor University. Medical Center) · 2024Article
- COVID-19 subphenotypes at hospital admission are associated with mortality: a cross-sectional study.Annals of medicine · 2023Article
- Does tocilizumab have an effect on the clinical outcomes in COVID-19 patients? A meta-analysis of randomized control trials.Journal of pharmaceutical policy and practice · 2023Article
- COVID-19 and Multiorgan Response: The Long-Term Impact.Current problems in cardiology · 2023Review
- COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs.RMD open · 2023Article
- Review
- Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review.BMJ medicine · 2023Article
- Article
- Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19).Journal of intensive medicine · 2022Article
Corrections and comments
- Commented on by
- Commented on by
- Comment on
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
34407334What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.